VIP Comparative Pharmacology — Research Reference
Vasoactive Intestinal Peptide (VIP) stands as a pivotal neuropeptide whose multifaceted roles are extensively investigated across vascular, immune, and neurobiological research domains. Classified as a vasoactive intestinal peptide, its primary mechanism involves modulating physiological processes through specific receptor interactions, driving a substantial body of scientific inquiry. The compelling evidence supporting VIP’s investigational utility is underscored by numerous publications indexed in PubMed, alongside several registered studies on ClinicalTrials.gov, reflecting a broad and sustained interest in its research applications.
This reference page provides a detailed exploration of VIP’s pharmacological profile within a research-use-only framework. It delves into the peptide’s structural characteristics, receptor pharmacology, intricate signaling pathways, and offers a comparative analysis with structurally and functionally related peptides. By synthesizing information on its observed effects in various preclinical models and outlining the sophisticated analytical methodologies employed for its study, this resource aims to equip researchers with a foundational understanding of VIP for their ongoing and prospective investigations. All discussions are strictly limited to research contexts, focusing on mechanisms and observations in experimental systems without implying any human therapeutic use or safety.
Structural and Molecular Characteristics of Vasoactive Intestinal Peptide
Vasoactive Intestinal Peptide (VIP) is a prominent neuropeptide belonging to the secretin/glucagon superfamily, characterized by its 28-amino acid polypeptide chain. Its primary structure, first elucidated from porcine duodenum, is remarkably conserved across species, indicating a critical evolutionary role. The sequence identity between human, rat, mouse, and porcine VIP is exceptionally high, typically 100% or very close to it, highlighting the uniformity of this molecule in various research models. This conservation is crucial for researchers investigating its physiological roles, as findings from preclinical models often possess strong translational relevance concerning the peptide’s inherent molecular interactions. The precise arrangement of these amino acids dictates not only its biological activity but also its physicochemical properties, which are fundamental considerations for any researcher working with this peptide. Understanding these intrinsic characteristics is paramount for experimental design, ensuring optimal handling, storage, and application within various research protocols. For further foundational understanding, researchers might refer to general information on what research peptides are.
Primary Structure and Sequence Homology
The amino acid sequence of VIP is H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2, terminating in a carboxyamide group that is essential for its full biological activity. This amidated C-terminus is a common feature among many neuropeptides and significantly impacts receptor binding affinity and proteolytic stability. The presence of several basic residues (arginine, lysine) alongside acidic residues (aspartic acid) contributes to its amphipathic nature, allowing it to interact effectively with both aqueous and lipid environments, which is crucial for its membrane receptor interactions. Variations, though minimal, can sometimes be observed in non-mammalian species, prompting careful consideration for comparative studies. The high degree of sequence homology underscores its conserved binding sites and functional domains, making it a reliable subject for cross-species pharmacological investigation, particularly when assessing its receptor interactions and downstream signaling.
Conformational Dynamics and Secondary Structure
While the precise three-dimensional structure of VIP *in vivo* is dynamic and context-dependent, structural studies employing techniques such as Circular Dichroism (CD) spectroscopy and Nuclear Magnetic Resonance (NMR) reveal a propensity for alpha-helical formation. In aqueous solutions, VIP typically adopts a flexible, random coil conformation. However, upon interaction with membrane-mimicking environments, such as detergents or lipid bilayers, or in the presence of its cognate receptors, VIP undergoes a conformational shift, acquiring significant alpha-helical content, particularly in its N-terminal region. This induced helical structure is critical for its receptor recognition and subsequent activation. The flexibility of VIP in solution allows for adaptable interactions, while its ability to assume a more ordered structure upon binding is a hallmark of many peptide hormones, facilitating specific and high-affinity receptor engagement necessary for initiating intracellular signaling cascades.
Physicochemical Properties and Stability
The physicochemical properties of VIP, including its molecular weight (approximately 3326 Da for human VIP), isoelectric point (pI), and solubility, are central to its handling and experimental utility. As a relatively small peptide, it is susceptible to degradation by various endopeptidases and exopeptidases *in vitro* and *in vivo*, contributing to its short biological half-life. This proteolytic vulnerability necessitates careful experimental design, including the use of protease inhibitors in biological samples and appropriate storage conditions. VIP is soluble in aqueous buffers at physiological pH, but its stability is highly dependent on temperature, pH, and the presence of oxidizing agents. Oxidation of methionine residues, for instance, can lead to a loss of biological activity. Therefore, researchers must adhere to stringent handling protocols, such as storage at ultra-low temperatures and reconstitution in sterile, appropriate buffers, often containing stabilizing agents, to maintain peptide integrity and bioactivity for reliable research outcomes. Detailed guidance on these aspects is often provided by manufacturers and should be rigorously followed by researchers.
VIP Receptor Systems: Subtypes, Signaling, and Desensitization
The biological actions of Vasoactive Intestinal Peptide (VIP) are mediated through its interaction with specific G protein-coupled receptors (GPCRs), primarily the Vasoactive Intestinal Peptide Receptors 1 and 2, denoted as VPAC1 and VPAC2, respectively. These receptors belong to the class B (or secretin-like) family of GPCRs, which are characterized by a large N-terminal extracellular domain involved in ligand binding and activation. The differential distribution and activation profiles of VPAC1 and VPAC2 receptors throughout various tissues and cell types underpin the diverse physiological roles attributed to VIP. For instance, VPAC1 is widely expressed in the immune system, gastrointestinal tract, and central nervous system, while VPAC2 predominates in the smooth muscle of the vasculature, pancreas, and certain neuronal populations. Understanding the specific receptor subtype involved in a particular cellular response is crucial for dissecting the precise mechanism of action of VIP in any given research model. Such detailed mechanistic insights are fundamental to advanced pharmacological studies, and researchers can find comprehensive information on the VIP mechanism of action for a deeper dive.
VPAC1 and VPAC2 Receptor Architecture and Distribution
Both VPAC1 and VPAC2 receptors are seven-transmembrane domain proteins, typical of GPCRs, sharing approximately 50% sequence homology in their transmembrane and intracellular domains, but exhibiting less conservation in their extracellular N-terminal domains. This N-terminal variation contributes significantly to their distinct ligand binding characteristics and selectivity. VPAC1 is highly expressed in cells of the immune system, including T-lymphocytes, monocytes, and dendritic cells, as well as in epithelial cells of the intestine and lung, and certain glial cells. VPAC2, conversely, is prominently found in vascular smooth muscle cells, pancreatic islet cells, and specific hypothalamic nuclei. The unique expression patterns mean that research investigating VIP’s role in inflammation or gut health might primarily implicate VPAC1, while studies focusing on cardiovascular effects or glucose homeostasis would more likely involve VPAC2. Furthermore, both receptors can be co-expressed in some cell types, potentially leading to complex integrated responses or even heterodimerization, which could modulate signaling further.
Intracellular Signaling Cascades
Upon VIP binding, both VPAC1 and VPAC2 receptors primarily couple to Gs proteins, leading to the activation of adenylyl cyclase (AC) and a subsequent increase in intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP then activates protein kinase A (PKA), which phosphorylates a wide array of target proteins, ultimately modulating gene expression, enzyme activity, and ion channel function. Beyond the canonical cAMP/PKA pathway, VIP receptor activation can also engage other signaling cascades. Some studies have indicated coupling to Gq proteins, leading to activation of phospholipase C (PLC) and an increase in inositol triphosphate (IP3) and diacylglycerol (DAG), which subsequently activate protein kinase C (PKC) and mobilize intracellular calcium. The extent of Gq coupling can vary based on receptor subtype, cell type, and even the specific VIP analog employed. The intricate interplay between these signaling pathways allows VIP to elicit highly diverse cellular responses, from vasodilation and immunomodulation to neurotransmission and metabolic regulation, requiring careful dissection in experimental models.
Mechanisms of Receptor Desensitization and Downregulation
Prolonged or repeated exposure to VIP often leads to a phenomenon known as receptor desensitization, where the cellular response to VIP diminishes despite continued ligand presence. This crucial regulatory mechanism prevents overstimulation and maintains cellular homeostasis. The primary mechanism involves phosphorylation of the activated receptor by G protein-coupled receptor kinases (GRKs), followed by the binding of arrestin proteins. Arrestin binding not only uncouples the receptor from its G protein, thereby terminating signaling, but also targets the receptor for internalization into endosomes. Once internalized, receptors can either be dephosphorylated and recycled back to the cell surface, restoring sensitivity (resensitization), or be targeted for lysosomal degradation, leading to a reduction in total receptor numbers on the cell surface (downregulation). The specific kinetics and extent of desensitization and downregulation can vary between VPAC1 and VPAC2, and across different cell types, influencing the temporal dynamics of VIP’s actions and presenting important considerations for *in vitro* and *in vivo* research designs that involve sustained VIP exposure.
Comparative Pharmacology of VIP and Related Peptides
The secretin/glucagon superfamily of peptides, to which Vasoactive Intestinal Peptide (VIP) belongs, is a diverse group of hormones and neuropeptides that share structural homology and often overlapping biological activities. Key members include secretin, glucagon, glucagon-like peptides (GLP-1 and GLP-2), gastric inhibitory polypeptide (GIP), and pituitary adenylate cyclase-activating polypeptide (PACAP). While these peptides share a common evolutionary origin and a similar overall tertiary structure, often involving an N-terminal alpha-helix crucial for receptor interaction, subtle differences in their amino acid sequences confer distinct pharmacological profiles. These differences are critical in determining their respective receptor selectivities, potencies, and ultimately, their unique physiological roles. Researchers investigating VIP must be cognizant of these relationships, as cross-reactivity or the use of pan-specific agonists/antagonists can confound experimental interpretations, necessitating precise pharmacological tools and careful experimental design to delineate VIP-specific effects from those mediated by related peptides.
VIP’s Structural Relatives and Functional Overlap
VIP shares the highest sequence homology and functional overlap with PACAP, particularly PACAP38 and its shorter variant PACAP27. Both VIP and PACAP can activate VPAC1 and VPAC2 receptors, although PACAP also binds with high affinity to a third receptor, PAC1, to which VIP has virtually no affinity. This differential receptor binding is a cornerstone of their distinct pharmacological profiles: VIP is generally considered a non-selective agonist for VPAC1 and VPAC2, while PACAP is a potent agonist for PAC1, VPAC1, and VPAC2. Secretin, while structurally related, primarily acts on the secretin receptor (SCTR) and has significantly lower affinity for VPAC receptors. Glucagon, GLP-1, GLP-2, and GIP each have their own cognate receptors (GCGR, GLP1R, GLP2R, GIPR, respectively) and exhibit even less cross-reactivity with VPAC receptors, though some very high concentrations might elicit minor non-specific effects. Understanding these hierarchical affinities is essential when using these peptides as research tools or comparators.
Receptor Selectivity and Potency Profiles
The subtle differences in amino acid sequence between VIP and its relatives translate into distinct receptor selectivity and potency. For instance, PACAP typically binds to VPAC1 and VPAC2 with comparable or slightly higher affinity than VIP, but its defining characteristic is its high affinity and potency for the PAC1 receptor. VIP, conversely, is often described as equipotent at VPAC1 and VPAC2 receptors, without significant activity at PAC1. Secretin demonstrates high selectivity for its own receptor (SCTR) and negligible affinity for VPAC receptors. The relative potencies of these peptides can be quantified using various *in vitro* assays, such as cAMP accumulation assays, which measure the half-maximal effective concentration (EC50) for receptor activation. These quantitative metrics are indispensable for selecting appropriate peptide concentrations in research experiments and for interpreting dose-response curves. The development of selective agonists and antagonists for each receptor subtype (e.g., highly selective VPAC1 or VPAC2 agonists/antagonists, or PAC1-selective compounds) has greatly advanced the ability of researchers to dissect the specific roles of each receptor in complex biological systems.
Synthetic Analogs and Pharmacological Tools
The short half-life and broad receptor activity of native VIP have driven significant research into the development of synthetic analogs with improved pharmacokinetic profiles, enhanced receptor selectivity, or antagonist properties. Modifications such as N-terminal acetylation, C-terminal amidation, amino acid substitutions (e.g., [K15, R16, L27]-VIP), or the incorporation of D-amino acids can yield peptides with increased resistance to enzymatic degradation, leading to prolonged duration of action in *in vivo* models. Furthermore, specific amino acid substitutions can confer selectivity for either VPAC1 or VPAC2 receptors, allowing researchers to probe the distinct physiological contributions of these subtypes. For example, certain VIP analogs exhibit increased potency for VPAC2 over VPAC1, while others are developed as potent antagonists of one or both receptors. These pharmacological tools are invaluable for dissecting the complex biology of VIP, enabling researchers to selectively activate or block specific signaling pathways and receptor-mediated responses in their experimental models, thereby providing clearer insights into the specific role of VIP receptors.
| Peptide | Primary Cognate Receptor(s) | Key Distinctive Feature | Relative Potency at VPAC1/VPAC2 (vs. VIP) |
|---|---|---|---|
| Vasoactive Intestinal Peptide (VIP) | VPAC1, VPAC2 | Equipotent agonist for VPAC1 and VPAC2, no PAC1 affinity. | High (Reference) |
| Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) | PAC1, VPAC1, VPAC2 | High affinity for PAC1; broad activity across PAC1, VPAC1, VPAC2. | High (similar to VIP) |
| Secretin | Secretin Receptor (SCTR) | Highly selective for SCTR, minimal VPAC activity. | Very Low |
| Glucagon | Glucagon Receptor (GCGR) | Primarily regulates glucose homeostasis via GCGR. | Negligible |
| Glucagon-like Peptide-1 (GLP-1) | GLP-1 Receptor (GLP1R) | Incretin hormone, regulates glucose-dependent insulin secretion. | Negligible |
Investigational Roles of VIP in Immune System Modulation Research
Vasoactive Intestinal Peptide (VIP) has garnered significant attention in immune system modulation research due to its well-documented anti-inflammatory and immunosuppressive properties. VIP is synthesized and released by both neuronal and immune cells, suggesting an autocrine and paracrine regulatory role within the neuro-immune axis. Its receptors, VPAC1 and VPAC2, are widely expressed on various immune cells, including T lymphocytes, B lymphocytes, macrophages, dendritic cells, and mast cells, allowing VIP to exert broad regulatory control over both innate and adaptive immune responses. The ability of VIP to modulate cytokine production, cell proliferation, migration, and survival makes it a compelling subject for investigating its potential in managing various inflammatory and autoimmune conditions in preclinical research models. Understanding these intricate interactions is crucial for delineating the full spectrum of VIP’s influence on immune cell function and host defense mechanisms.
Immunoregulatory Actions on Lymphocytes and Phagocytes
VIP exerts profound immunomodulatory effects on lymphocytes, particularly T helper (Th) cells. Research indicates that VIP can suppress the proliferation of activated T cells and skew their differentiation towards a Th2 phenotype, which is associated with humoral immunity, or towards regulatory T cells (Tregs), which are critical for maintaining immune tolerance and preventing autoimmunity. Concurrently, VIP has been shown to inhibit the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IFN-γ from Th1 cells, while promoting the release of anti-inflammatory cytokines like IL-10. In macrophages and dendritic cells, VIP primarily acts to reduce the production of pro-inflammatory mediators and enhances their phagocytic activity without excessively activating them, thus promoting a state of immune resolution rather than exacerbation. This multifaceted influence on key immune cell populations highlights VIP’s potential as an endogenous regulator of immune homeostasis.
Cytokine Profile Modulation
One of the most significant aspects of VIP’s immunomodulatory activity is its capacity to reshape the cytokine milieu. By activating VPAC receptors, primarily VPAC1, on immune cells, VIP leads to increased intracellular cAMP levels, which in turn can inhibit the transcription and release of numerous pro-inflammatory cytokines. This includes a robust suppression of TNF-α, a master cytokine in inflammation, as well as IL-6, IL-1β, and various chemokines that drive immune cell recruitment to inflammatory sites. Conversely, VIP can enhance the production of the anti-inflammatory cytokine IL-10, which plays a crucial role in suppressing immune responses and promoting tissue repair. This ability to concurrently downregulate pro-inflammatory and upregulate anti-inflammatory cytokines positions VIP as a potent modulator of the inflammatory cascade, suggesting its investigational relevance in conditions characterized by cytokine storm or chronic inflammation in research models.
Research in Inflammatory and Autoimmune Models
A substantial body of preclinical research has investigated the efficacy of VIP in various models of inflammatory and autoimmune diseases. Studies in models of rheumatoid arthritis have shown that VIP administration can reduce joint inflammation and bone erosion by suppressing synovial inflammation and immune cell infiltration. In models of inflammatory bowel disease (IBD), VIP has demonstrated the capacity to reduce colonic inflammation, restore gut barrier function, and modulate the gut microbiota composition. Furthermore, research in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis, has indicated that VIP can ameliorate disease severity by reducing demyelination and promoting neuroprotection through its immunoregulatory effects on T cells and glial cells. These findings underscore VIP’s broad therapeutic potential in preclinical settings, prompting further investigation into its specific mechanisms and optimal delivery strategies for specific disease contexts.
VIP’s Influence in Vascular Homeostasis Research Models
Vasoactive Intestinal Peptide (VIP) is widely recognized for its potent vasodilatory properties and its significant role in maintaining vascular homeostasis. As a neuropeptide, VIP is extensively distributed in the nervous system, particularly in perivascular nerve fibers, where it acts as a neurotransmitter and neuromodulator. Its release from these nerve endings into the local microenvironment directly influences vascular tone, blood flow regulation, and the overall integrity of the vasculature. The interaction of VIP with its VPAC1 and VPAC2 receptors, particularly VPAC2 which is highly expressed on vascular smooth muscle cells, leads to a cascade of events culminating in vasodilation. Research into VIP’s vascular effects spans a wide range of physiological and pathological contexts, from systemic blood pressure regulation to local tissue perfusion and protection against vascular injury. Understanding VIP’s intricate actions on the vascular system provides critical insights into potential investigational approaches for conditions involving dysregulated vascular function.
Vasodilatory Mechanisms and Vascular Tone
VIP’s primary and most well-characterized vascular effect is its potent ability to induce vasodilation, leading to a reduction in systemic and regional vascular resistance. This effect is largely mediated by the activation of VPAC2 receptors on vascular smooth muscle cells. Upon VIP binding, VPAC2 receptors primarily couple to Gs proteins, activating adenylyl cyclase and increasing intracellular cAMP levels. Elevated cAMP then activates protein kinase A (PKA), which phosphorylates several target proteins, leading to a decrease in intracellular calcium concentrations and subsequent relaxation of smooth muscle. This includes the phosphorylation of myosin light chain kinase (MLCK), reducing its sensitivity to calcium, and the activation of K+ channels, leading to hyperpolarization and reduced excitability of the smooth muscle cells. The resulting smooth muscle relaxation causes the vessels to widen, increasing blood flow. This direct action on vascular smooth muscle cells makes VIP a significant endogenous regulator of vascular tone and blood pressure in various research models.
Endothelial Protective Effects
Beyond its direct vasodilatory actions, VIP also exerts significant protective effects on the vascular endothelium, the inner lining of blood vessels. Research indicates that VIP can enhance endothelial barrier function, reducing vascular permeability and preventing extravasation of fluids and immune cells, which is crucial in inflammatory conditions. VIP has also been shown to promote endothelial cell survival and inhibit apoptosis, particularly under conditions of oxidative stress or inflammation. Furthermore, studies suggest VIP can modulate the production of nitric oxide (NO) and prostacyclin (PGI2) by endothelial cells, both of which are critical vasodilators and anti-thrombotic agents. By preserving endothelial integrity and function, VIP contributes to the overall health and stability of the vascular system, offering investigational avenues for conditions characterized by endothelial dysfunction, such as atherosclerosis or hypertension, in preclinical models.
Research in Ischemia and Reperfusion
VIP has shown promising investigational potential in models of ischemia-reperfusion (I/R) injury, a common pathological process occurring in conditions like myocardial infarction, stroke, or organ transplantation. In I/R injury, blood flow to an organ is temporarily interrupted (ischemia) and then restored (reperfusion), leading to tissue damage caused by oxidative stress, inflammation, and endothelial dysfunction. Preclinical studies have demonstrated that VIP administration prior to or during reperfusion can significantly attenuate I/R injury in various organs, including the heart, brain, kidney, and liver. Its protective effects in these models are attributed to its vasodilatory actions, which improve microvascular perfusion, its anti-inflammatory properties, which reduce the influx of damaging immune cells and cytokine release, and its direct cytoprotective effects on endothelial cells and cardiomyocytes. These multi-pronged mechanisms underscore VIP’s capacity to mitigate the complex pathogenesis of I/R injury, making it a compelling subject for ongoing research in tissue protection strategies.
Neuroendocrine and Neuromodulatory Research Applications of VIP
Vasoactive Intestinal Peptide (VIP) holds a prominent position within the field of neuroendocrine and neuromodulatory research due to its widespread distribution and diverse actions within both the central and peripheral nervous systems, as well as its intricate interplay with endocrine glands. Synthesized and released by specific neuronal
Frequently Asked Questions
What is the primary classification of Vasoactive Intestinal Peptide (VIP)?
VIP is classified as a vasoactive intestinal peptide, belonging to the secretin/glucagon superfamily of peptide hormones. This classification reflects its historical discovery and its observed broad influence on various physiological systems in research models.
What is the main mechanism of action investigated for VIP in research?
In research, VIP’s main mechanism involves acting as a neuropeptide that binds to specific G-protein coupled receptors, primarily VPAC1 and VPAC2. This binding typically leads to the activation of adenylate cyclase and an increase in intracellular cyclic AMP (cAMP) levels, mediating a range of downstream cellular effects in experimental systems.
How many PubMed publications are indexed for VIP research?
There are numerous PubMed publications indexed for VIP research, indicating a vast and continually expanding body of scientific literature dedicated to understanding its structure, function, and investigational potential in various biological contexts.
Are there studies on ClinicalTrials.gov related to VIP?
Yes, there are several registered studies on ClinicalTrials.gov related to VIP. These entries primarily denote investigational research aimed at exploring VIP’s physiological roles and potential mechanisms in preclinical or early-phase exploratory human research, strictly within a research-use-only scope.
What are common aliases for Vasoactive Intestinal Peptide?
The most common alias for Vasoactive Intestinal Peptide is simply its full name: Vasoactive Intestinal Peptide. While VIP is the widely recognized acronym, using the full name can ensure clarity in scientific communication.
How does VIP differ from PACAP in a research context?
In a research context, VIP and PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) are structurally related and share common receptors (VPAC1 and VPAC2). However, PACAP also binds to a distinct receptor, PAC1, with high affinity, leading to some divergent downstream signaling and observed effects in various research models, enabling researchers to distinguish their individual roles.
What analytical methods are commonly used to study VIP in research?
Common analytical methods for studying VIP in research include immunoassays such as ELISA and RIA for quantification, chromatographic techniques like HPLC and LC-MS/MS for separation and identification, and receptor binding assays or functional assays (e.g., cAMP accumulation) to assess its biological activity and receptor interactions in vitro.
What kind of research areas typically investigate VIP?
Research areas that typically investigate VIP are broad, encompassing immunology, vascular biology, neurobiology, endocrinology, and gastroenterology. Studies frequently explore its roles in inflammation, vasodilation, neuroprotection, and regulation of various physiological processes in diverse preclinical models.
Scientific References
All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.